Category: Featured

By Bonni Goldstein, MD

View the featured webinar here 

 

Dr. Goldstein’s recent presentation explored the emerging evidence on the role of cannabinoids in managing symptoms associated with Autism Spectrum Disorder (ASD). She highlighted both the scientific foundation and her own clinical experience with cannabinoid-based therapies in her pediatric patients. 

 

 

Background

 

Autism Spectrum Disorder is a complex neurodevelopmental condition often accompanied by behavioral, social, and medical challenges. There are two FDA approved medications which unfortunately offer limited benefits and can cause significant short- and long-term side effects. There has been significant interest in targeting the body’s endocannabinoid system (ECS) in individuals struggling with challenging symptoms of autism as this widespread system helps regulate mood, focus, sleep, immune response, and inflammation.

 

 

The Endocannabinoid System and ASD

 

Research suggests that individuals with ASD may have imbalances in their ECS, including alterations in endocannabinoid and cannabinoid receptor levels. These differences are thought to contribute to neuroinflammation, disrupt immune function, and create gut-brain imbalances.  Plant cannabinoids such as CBD and THC may help restore balance by reducing inflammation and enhancing brain-body communication through interactions with the ECS, promoting homeostasis.

 

 

Clinical Evidence

 

Dr. Goldstein reviewed numerous clinical trials and case studies:

 

• Children and adolescents with ASD treated with CBD:THC ratios (typically 20:1, with a few studies looking at higher and lower ratios) showed improvements in irritability, agitation, sleep, anxiety, social engagement, aggression, and speech/language. 
• Studies report behavioral improvements in 61–93% of participants, with mild, manageable side effects such as drowsiness or appetite changes.
• Combination cannabinoid regimens may provide better results due to synergistic effects.
• Dr. Goldstein presented results from her research demonstrating that parent-reported behavioral improvements following medical cannabis treatment were associated with shifts in salivary biomarkers of aggression, inflammation, and other physiologic pathways toward neurotypical levels. 

 

 

Clinical Pearls

 

Dr. Goldstein emphasized a personalized, methodical approach as there is no “one size fits all” for cannabinoid treatments. 

 

• The scientific literature supports the use of CBD-dominant products first with the addition of other cannabinoids as needed.
• Challenges of aggression towards other or self or severe insomnia may require lower CBD:THC ratios. 
• Watch for biphasic effects of CBD, as lower doses may be overstimulating while higher doses are often more calming. 
• Adjusting doses on the weekends or while the child is under parental supervision is advised (i.e., it is not recommended to send your child to school on a new product or dose until you’ve seen how they respond at home) 

 

Summary: Cannabinoid-based treatments show promise in addressing the behavioral and physiological challenges of ASD. They are safe and well-tolerated under medical supervision, and may reduce the need for traditional medications. Ongoing research continues to refine dosing, ratios, and cannabinoid combinations for individualized care.

 

 

Q and A: 

 

Question: Does this mean cannabinoids that activate CB2R could cause improvements? THC activates CB1 and CB2. Tolerance means that CB1R decrease, but CB2R do not show tolerance. Could this mean that CB2R activation is important in regulating autism?

Answer: Yes. Activating CB2 receptors may help improve autism-related symptoms as they are involved in reducing inflammation and regulating the immune system. Since THC activates both CB1 and CB2 receptors, but only CB1 develops tolerance, the lasting effects may be linked more to CB2 activation. Beta-caryophyllene is a terpene (essential oil) found in many plants, including cannabis. This safe compound is unique in that it targets CB2 receptors without activating CB1 receptors, eliminating the risk of impairment and tolerance. 

 

Question: How hard or expensive is checking ECS biomarkers?

Answer: It is quite easy to check biomarkers with the technology used in my research. The biotech company I partnered with to do this research, Cannformatics, has a testing kit that will be available in the next year. The test can be mailed to the patient’s home and requires the collection of a small amount of saliva. The kit is shipped to the testing facility and the results are emailed to the patient and their clinician. 

Question: Do we have studies yet that explore cannabis use during pregnancy, and does use impact the fetus to be more likely born deficient in their endocannabinoids?

Answer: There are several studies that have explored the use of THC during pregnancy. It appears that use during pregnancy may result in lower birth weight, and possibly later issues with attention, behavior, and executive function. Interestingly, a 2024 study of 178,948 pregnancies found that prenatal use of cannabis was not associated with a later diagnosis of autism (Avalos, et al., 2024). There are no human studies that have investigated the use of CBD during pregnancy, however animal studies show some potential adverse effects on the fetus.

Question: What elements of full spectrum do you feel are enhancing autism benefits? cannabinoids and terpenes?

Answer: My patients with autism have benefitted from many different cannabinoids and terpene combinations. CBD+THC is by far the most common starting point for patients, as the scientific literature shows about 75% will have some therapeutic benefits with these two cannabinoids. I encourage parents to trial all the available cannabinoids to figure out the best regimen for their child’s needs. There are several terpenes that seem to help, including linlool, myrcene, beta-caryophyllene, borneol and others. Some CBD companies offer the addition of terpenes to their products to provide more customized formulations. Medical guidance can help tremendously when going through this journey!

Question: Here in Australia, there is a big concern around the use of high dose THC, particularly in patients with a potential for worsening paranoia and other symptoms, or in those who may be predisposed to developing schizophrenia. You mentioned that you do not judge the dose that patients take when reviewing the UK study on adult ASD patients. In your opinion, how can clinicians balance this risk with high dose THC in patients who may require it to function? Is there any correlation between ASD and the propensity to develop schizophrenic symptoms?

Answer: Medical cannabis use and recreational THC use are not comparable. Clinically supervised regimens rarely involve high-dose THC alone, as this can lead to tolerance and reduced therapeutic benefit. Most cannabis clinicians will recommend the inclusion of CBD as it can mitigate tolerance and often enhances beneficial effects (Sacco et al., 2024). The UK study on adults with ASD noted a preference for higher-THC products, likely due to prior cannabis use and existing tolerance rather than an initial medical recommendation for high-dose THC. While ASD and schizophrenia share some overlapping features, ASD itself does not increase the likelihood of developing schizophrenia. The current thought is that adolescents who are at risk for schizophrenia from THC are typically chronic heavy users with a genetic susceptibility, specifically a first-degree relative with schizophrenia or another significant mental health disorder.

 

Question: How do you respond to concerned parents who ask about the potential neurodevelopmental side-effects of THC in children?

Answer: The potential neurodevelopmental side effects that concern parents and some clinicians stem from studies on chronic, heavy recreational use of THC in teenagers, not from medically supervised and customized cannabinoid regimens. In medical settings, THC is titrated to the minimum effective dose, meaning the lowest dose that gives the best results without unwanted side effects. This minimizes risks and avoids impairment. In my experience, children using THC as part of a balanced regimen often demonstrate neurodevelopmental progress. 

 

Question: Would you consider use of BCP in autism?

Answer: Yes. I have several patients who are using beta-caryophyllene for symptoms of autism, usually in combination with other cannabinoids. 

Question: Regarding some studies showing that liver enzymes increase after cannabinoid use: should patients be concerned in using CBD, CBG, and/or THC long term to avoid liver injury?

Answer: In my clinical experience, full-spectrum CBD formulations rarely cause elevated liver enzymes unless patients are taking other medications that also stress the liver, such as certain anticonvulsants or chemotherapy. These patients should have bloodwork at least every 6 months.  Elevations of liver enzymes are typically mild and completely reversible once CBD or the interacting medication is discontinued. It appears that purified high-dose CBD isolates are more likely to cause increases in liver enzymes compared to full-spectrum CBD. Currently, there are no published human reports linking CBG to liver injury, although one preclinical study showed low doses of CBG to be liver protective and much higher doses to cause injury (Snell and Tesch, 2021). Regarding THC, studies of medical cannabis patients do not show evidence of liver toxicity. 

Question: Several of my patients with autism experience some hyperactivity when they start cannabis treatment. It usually lasts about a week, so I always tell the parents this can happen. Have you noticed something similar?

Answer: Yes, I have seen this as well. Studies show that low doses of CBD can be stimulating or alerting, which may worsen hyperactivity or agitation in children who are already overstimulated. Because treatment typically begins with low doses, preparing parents for this potential effect is helpful so that they don’t discontinue treatment too early. Conversely, CBD can be calming at higher doses, so if increased hyperactivity or behavioral issues occur, parents should be instructed to continue to titrate up the dose. Interestingly, when higher doses are reached, children may appear more relaxed or “mellow” for up to 7 days before getting used to the new dose. If a child remains overly sedated after a week on a higher dose, I recommend slowly reducing the dose to identify the level that provides the most benefit without unwanted drowsiness.

 

 

Bonni Goldstein, MD is the Medical Director of Canna-Centers Wellness & Education, a cannabis medicine specialty practice in Los Angeles, and the CEO of GoldsteinWellness.com, an educational platform dedicated to helping licensed healthcare professionals incorporate medical cannabis and hemp into their practices, as well as connect patients with knowledgeable practitioners. 

 

Dr. Goldstein has evaluated thousands of patients for medical cannabis treatment over the past 18 years. She has a special focus on treating children with intractable epilepsy, autism, and cancer. She has co-authored numerous papers on the use of pharmacometabolomics to study the impact of medical cannabis on the behavioral symptoms associated with autism. Dr. Goldstein is the author of the book Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. She is a medical advisor to numerous companies, including Cannformatics, Neurotech International LLC, and Weedmaps.com. 

 

 

Sources:

 

Aran, A., Hacohen, M., Caspi, L., & Lavi, I. (2019). Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—a retrospective feasibility study. Journal of Autism and Developmental Disorders, 49(3), 1284–1288.

 

Aran, A., Eylon, M., Harel, M., Polianski, L., Nemirovski, A., Tepper, S., Bentur, Y., & Castellanos, F. X. (2019). Lower circulating endocannabinoid levels in children with autism spectrum disorder. Molecular Autism, 10(1), 2.

 

Aran, A., et al. (2021). Cannabinoid treatment for autism: A proof-of-concept randomized trial. Molecular Autism, 12(1), 6.

 

Avalos, L. A., Hendrick, C. E., Li, D.-K., Quesenberry, C. P., Gorman, J. R., & Croen, L. A. (2024). Maternal prenatal cannabis use and child autism spectrum disorder. JAMA Network Open, 7(10), e2440301–e2440301.

 

Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019). Real life experience of medical cannabis treatment in autism: Analysis of safety and efficacy. Scientific Reports, 9(1), 200.

 

El-Sukkari, D., et al. (2023). Safety and efficacy of orally administered full-spectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in children with autism spectrum disorder: An open-label study. MedRxiv. https://doi.org/10.1101/2023.12

 

Erridge, S., et al. (2022). Clinical outcome analysis of patients with autism spectrum disorder: Analysis from the UK Medical Cannabis Registry. Therapeutic Advances in Psychopharmacology, 12, 20451253221116240.

 

Fleury-Teixeira, P., Caixeta, F. V., Ramires da Silva, L. C., Brasil-Neto, J. P., Malcher-Lopes, R., & Ribeiro, A. M. (2019). Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use. Frontiers in Neurology, 10, 1145.

 

Fletcher, S., Arnold, C., Houghton, R., & Little, S. (2022). Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review. Child: Care, Health and Development, 48(1), 33–44.

 

Hacohen, M., Aran, A., Eylon, M., & Meiri, G. (2022). Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: An open-label study. Translational Psychiatry, 12(1), 375.

 

Hurley, E. N., Cutshall, N. S., Eaton, E. A., Reisinger, D. L., Sutcliffe, J. S., & Anderson, A. E. (2022). Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia, 63(7), 1736–1747.

 

Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., Garner, J. P., Hardan, A. Y., & Parker, K. J. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9(1), 18.

 

Kurz, R., & Blaas, K. (2010). Use of dronabinol (delta-9-THC) in autism: A prospective single-case study with an early infantile autistic child. Cannabinoids, 5(4), 4–6.

 

Mazza, J. A. de S., Knap, L. M., de Souza, M. P., Silva, A. L. B., & Crippa, J. A. (2024). Clinical and family implications of cannabidiol (CBD)-dominant full-spectrum phytocannabinoid extract in children and adolescents with moderate to severe non-syndromic autism spectrum disorder (ASD): An observational study on neurobehavioral management. Pharmaceuticals, 17(6), 686.

 

Pretzsch, C. M., et al. (2019). Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without autism spectrum disorder (ASD): A single dose trial during magnetic resonance spectroscopy. Translational Psychiatry, 9(1), 313.

 

Sacco, R., Riccitelli, G. C., Disanto, G., Bogousslavsky, J., Cavelti, A., Czell, D., … & Zecca, C. (2024). Effectiveness, Safety and Patients’ Satisfaction of Nabiximols (Sativex®) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study. Journal of Clinical Medicine, 13(10), 2907.

 

Siani-Rose, M., Cox, S., Goldstein, B., Abrams, D., Taylor, M., & Kurek, I. (2023). Cannabis-responsive biomarkers: A pharmacometabolomics-based application to evaluate the impact of medical cannabis treatment on children with autism spectrum disorder. Cannabis and Cannabinoid Research, 8(1), 126–137.

 

Silva Junior, E. A. da, et al. (2024). Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind, and placebo-controlled clinical trial. Trends in Psychiatry and Psychotherapy, 46, e20210396.

 

Siniscalco, D., Sapone, A., Giordano, C., Cirillo, A., de Novellis, V., de Magistris, L., Rossi, F., & Maione, S. (2013). Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. Journal of Autism and Developmental Disorders, 43(11), 2686–2695.

 

Snell, A., & Tesch, T. (2021). Cannabigerol Effects on Body and Liver Weights in Methionine-& Choline-Deficient Diet Induced NASH Mice Model.

 

Stolar, O., et al. (2022). Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. Frontiers in Pharmacology, 13, 977484.

 

Zamberletti, E., Rubino, T., & Parolaro, D. (2021). Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. Pharmacology & Therapeutics, 226, 107878.

 

Zamberletti, E., Gabaglio, M., Woolley-Roberts, M., Cenini, G., Parolaro, D., & Rubino, T. (2019). Cannabidivarin treatment ameliorates autism-like behaviors and restores hippocampal endocannabinoid system and glia alterations induced by prenatal valproic acid exposure in rats. Frontiers in Cellular Neuroscience, 13, 367.

 

October 2025 has delivered three significant events: scientific validation of cannabis’s role in pain care, a major constitutional case bridging cannabis use and firearms law, and a consumer-market milestone with THC-beverages hitting mainstream retail. For the Realm of Caring community, these developments reinforce the need for research-informed patient education, advocacy on rights and access, and vigilance around emerging markets and regulatory frameworks.

 

1. Medical Cannabis Access Linked to Reduced Opioid Use in Cancer Patients

 

A federally-funded study published in JAMA Health Forum finds that opening medical or adult-use cannabis dispensaries is significantly associated with reductions in opioid prescriptions among patients diagnosed with cancer. 

 

• Researchers used data from 2007–2020 on about 3 million commercially-insured cancer patients.
• Findings: after cannabis dispensaries opened, the rate of patients with opioid prescriptions dropped by about 41.07 per 10,000 (95 % CI: –54.78 to –27.36). 
• The mean number of opioid prescriptions per patient fell, and mean days’ supply decreased by ~2.54 days.
• Implication: This suggests cannabis may serve as a substitute (or complement) to opioids in cancer-pain management, reinforcing the role of expanded medical-marijuana access amid the opioid crisis.
• For the Realm of Caring community this underscores the importance of patient-centred access, research, and inclusion of cannabis in therapeutic dialogues.

 

Take-away: For patients and clinicians alike, the evidence continues to mount that cannabis access can change prescribing patterns and pain-care options.

 

2. Supreme Court Takes Up Cannabinoids & Gun Rights

 

The Supreme Court of the United States has agreed to hear United States v. Hemani, a landmark case that asks whether individuals who use marijuana (even in states where it is legal) may be barred under federal law from owning firearms.

 

• The case centers on 18 U.S.C. § 922(g)(3), which forbids firearm possession by “unlawful user[s] of or addicted to any controlled substance.” 
• The Court’s decision to grant cert means we’ll likely see oral arguments in the 2025-26 term, with a decision anticipated 2026. 
• Impact: Because cannabis remains federally illegal (Schedule I) even if legal under state law, many users face conflict between state-legal activity and federal prohibitions.
• For the Realm of Caring audience: This case is vital because it touches on civil rights, medical-patient protections, reform-policy and how cannabis usage intersects with broader legal frameworks.

 

Take-away: The outcome could reshape how federal law treats cannabis-using patients and might remove a major barrier for many people in the cannabis space.

 

3. Mainstream Retail Embraces THC Beverages

 

Global retailer Target has rolled out a pilot program selling hemp-derived THC-infused beverages in select Minnesota locations, an important milestone for cannabis-adjacent consumer goods.

 

• The pilot includes about a dozen THC-beverage brands in ~10 Twin Cities stores.
• The offerings are draw­ing industry attention as mainstream retailers test the waters of cannabis-derived products.
• Regulatory context: This launch comes amid federal and state discussions about hemp-derived THC rules, and how intoxicating hemp products should be regulated.
• For Realm of Caring stakeholders: This signals that the cannabis-consumer sector is evolving fast, both for medical and wellness markets. Patient-advocacy, quality control, education and safety all become more important in this phase of normalization.

 

Take-away: As THC-beverages enter big-box shelves, the cannabis world crosses into everyday commerce, bringing opportunities and responsibility for education, regulation and patient safety.

 

Stay tuned here for continuing coverage and in-depth resources on how each of these trends may affect patients, caregivers, clinicians and reformers.

Background

 

Three nonprofits: Realm of Caring, Unlimited Sciences, and Lily’s Lighthouse, came together with a shared goal: to explore the therapeutic potential of functional mushrooms for people living with epilepsy. Each organization brings unique expertise, united by a shared commitment to expanding health and wellness options through research. Together, they aim to improve access to safe, science-backed, and natural therapies that enhance quality of life for individuals and families affected by epilepsy and other chronic conditions.

 

Together, these organizations designed and published a first-of-its-kind mixed-methods study investigating the effects of two well-known functional mushrooms, Reishi (Ganoderma lucidum) and Lion’s Mane (Hericium erinaceus), as either complementary or stand-alone therapies for epilepsy.

 

Why Lion’s Mane and Reishi?

 

Functional mushrooms have long been valued for their neuroprotective, antioxidant, and anti-inflammatory properties.

 

• Reishi, also known as “Ling Zhi,” has been used in traditional Chinese medicine for over 2,000 years. Modern research supports its potential to strengthen the immune system, improve sleep, and exhibit anti-seizure effects. 
• Lion’s Mane is recognized for promoting nerve growth factor (NGF) production and supporting cognitive function. In animal models, it has shown neuroprotective effects against seizure-related brain injury. 

Given their safety profiles and accessibility, these mushrooms present an intriguing opportunity for individuals whose seizures remain uncontrolled despite conventional treatments.

 

The Study

 

The study titled “Functional Mushrooms Saved My Daughter’s Life: A preliminary mixed methods survey study of Reishi (Ganoderma lucidum) and lion’s mane (Hericium erinaceus) for epilepsy” enrolled 19 participants, including adults with epilepsy and caregivers responding on behalf of minors. The majority (73.7%) met criteria for drug-resistant epilepsy (DRE), meaning seizures persisted despite using at least two anti-seizure medications.

 

Participants completed a comprehensive survey and an optional interview assessing mushroom use, seizure activity, sleep, quality of life (QoL), and caregiver burden. Data collection occurred between March and July 2024.

 

Key Findings

 

The results were compelling:

 

• 94.7 % of participants reported a positive impact of functional mushrooms on the way seizures affected their life

 

• 68.4 % reported at least some reduction or a significant reduction in both the severity and frequency of seizures (across varying seizure types and including those considered DRE) 
• 57.9 % reported a change in the frequency of hospital or physician-related visits 
• The Patient’s Global Impression of Change (PGIC) scores indicated 84.2 % of respondents reported a moderate to significant improvement in their diagnoses. 
• Only one mild adverse effect was reported (minor gastrointestinal discomfort). 

 

Beyond seizure control, qualitative data revealed six themes that highlight broader health and emotional benefits:

 

1. Improved seizure control: Many participants reported shorter, less severe, or entirely absent seizures. 
2. Cognitive and developmental gains: Caregivers observed improvements in speech, memory, and learning milestones. 
3. Better quality of life: Participants noted enhanced mood, reduced fatigue, and increased social engagement. 
4. Uncertainty around dosing: Participants expressed a desire for more information about effective dosing ranges. 
5. Dissatisfaction with conventional treatments: Many turned to mushrooms after exhausting traditional options that carried harsh side effects. 
6. A call for holistic, evidence-based care: Caregivers emphasized the need for research and open-minded medical guidance for natural therapies. 

 

As one caregiver poignantly shared:

 

“My daughter’s seizures completely stopped and haven’t returned after introducing Reishi mushroom powder.”

 

What These Results Suggest

 

Although preliminary, this research suggests that functional mushrooms could play a valuable complementary role in managing epilepsy, especially for those with treatment-resistant forms.

 

Importantly, quantitative data revealed that participants using mushrooms achieved comparable scores in physical, psychological, and social health to the general population. This is an encouraging sign for a population often reporting lower quality of life due to chronic symptoms and stress.

 

Additionally, correlations between caregiver burden and seizure severity reinforce how even small improvements in seizure control can profoundly impact entire families.

 

The Path Forward

 

While these findings are promising, they are not yet conclusive. Controlled clinical trials are essential to confirm the efficacy, optimal dosing, and mechanisms of action of Reishi and Lion’s Mane for epilepsy. The current study provides a foundation for future hypothesis-driven research, validating what many families already report anecdotally about complementary/adjunctive natural therapies.

 

As one participant summarized, “We obviously want to help with any form of potential treatment for families in the future so that they don’t struggle the way we’ve struggled.”

 

Practical Integration

 

For individuals or caregivers curious about functional mushrooms:

 

• Start a conversation with a healthcare provider familiar with integrative or complementary therapies. 
• Look for quality products that are third-party tested and organically sourced. 
• Track progress in a journal to monitor changes in seizure activity, mood, or sleep.

 

 

 

Read the Full Study

 

This collaboration between Realm of Caring, Unlimited Sciences, and Lily’s Lighthouse reflects a growing commitment to exploring safe, natural, and accessible interventions for complex conditions like epilepsy.

 

Read the full open-access study published in Pharmacological Research: Natural Products here.

 

To learn more, reach out to a Realm of Caring Care Specialist, visit Unlimited Sciences, or head to Lily’s Lighthouse.

As the Halloween candy aisle looms and sugar consumption spikes, many Americans are becoming increasingly aware of just how detrimental excess sugar can be for our health. What if there were more to maintaining healthy blood-sugar control than simply cutting sweets? Emerging research into cannabinoids, especially Cannabidiol (CBD),  suggests they may play a role in how our bodies process sugar and regulate metabolism. For people at risk of type 2 diabetes, or those simply hoping to support balanced sugar metabolism while still navigating seasonal indulgences, it is worth exploring what the science shows, what remains speculative, and how cannabinoids might potentially assist alongside (not instead of) established lifestyle and wellness regimens. 

 

Why Sugar Metabolism Matters Right Now

 

Sugar, or glucose, metabolism is the process by which energy in the foods we eat is made available as fuel for the body. After we eat, our pancreas releases insulin, a hormone that helps move glucose from the bloodstream into our cells for energy or storage. However, when this system is overloaded, either from excessive sugar intake or too little activity, insulin sensitivity can decrease. This means the body needs more insulin to get the same effect, setting the stage for higher blood sugar levels and metabolic challenges. 

 

Maintaining balanced glucose levels is essential for people living with diabetes or are prediabetic as well as those seeing sustained energy and overall wellness. 

 

Introducing the Endocannabinoid System (ECS) and Cannabinoids

 

The ECS helps to regulate several bodily processes. This includes appetite, mood, pain, inflammation, and energy balance. It is composed of receptors found throughout the body and brain, including those areas involved in metabolism: fat cells, liver, and muscles. 

 

Cannabidiol (CBD) is one of major, non-intoxicating, phytocannabinoids found in Cannabis sativa with researched antioxidant, anti-inflammatory, antipsychotic, and anxiolytic properties. It has been reported to have therapeutic effect on diabetes, cardiovascular diseases, cancers, and neurodegenerative diseases; attributed to its potent antioxidant properties. 

 

What Research Shows So Far: Considering Obesity and Type 2 Diabetes

 

Data is limited for cannabinoids and metabolic processes; however when it comes to glucose homeostasis, CBD appears to maintain it while sensitizing adipose tissue to insulin, and reducing fasting glucose levels. 

 

A 2013 published study further investigated findings from previous epidemiological studies that found lower prevalence rates of obesity and diabetes mellitus in cannabis users compared to those who have never used cannabis. Their results found that cannabis use (not specifically CBD) was associated with 16% lower fasting insulin levels and a significant association between cannabis use and smaller waist circumferences. 

 

A more recently published study, in March of 2025, provides strong evidence of CBD’s antidiabetic potential, particularly through its ability to modulate glucose metabolism and tendency to regulate insulin levels. 

 

What Research Shows So Far: Additional Health Risks Attributed to Excessive Sugar

 

Studies show that high sugar intake may be attributed to increased inflammation, heart disease, elevated blood pressure, and cognitive decline. 

 

CBD has been researched for the many ways it may benefit our heart health, some of the most notable therapeutic actions of the molecule are the anti-inflammatory and antioxidant properties. The therapeutic potentials of CBD are why it is being considered in research for the prevention and treatment of these conditions and diseases. In addition, CBD has particularly gained momentum because it does not appear to have effects on resting blood pressure or heart rate, rather it has shown in vivo to reduce the cardiovascular response to various stress types. 

 

Prolonged CBD therapy has shown positive improvements in psychological symptoms and cognition. Currently, using cannabinoids to benefit neurological issues and serve as a neuroprotectant is being studied. The antioxidant properties of cannabinoids, such as CBD, may have the ability to provide neuroprotection. As well, research is showing that elevation of cannabinoid receptor activity could potentially slow down the progression of brain ageing and alleviate symptoms associated with neurodegenerative disorders, therefore cannabinoids with the ability to activate receptors may provide these additional benefits.

 

Practical Integration: CBD as a Supportive Tool

 

If you’re curious about using CBD to support a balanced metabolism (or for other health concerns), here are a few practical tips to keep in mind as you incorporate it into your holistic wellness routine: 

 

CBD is not a cure or replacement for healthy habits. Balanced nutrition, regular physical activity, hydration, and sleep remain the cornerstones of blood sugar health.

 

Quality matters. Choose products that are third-party tested, clearly labeled, and sourced from reputable brands. Realm of Caring’s Care Team can help guide you toward safe, evidence-based options.

 

Start low and go slow. The right dose can vary widely depending on the individual, product type, and health goals.

 

Talk with your healthcare provider. CBD may interact with certain medications, including those that affect blood sugar or liver enzymes.

 

Timing and mindfulness. Around high-sugar events (like Halloween), pairing CBD with mindful eating, fiber-rich snacks, and post-meal activity can all contribute to steadier glucose levels.

 

Looking Ahead

 

Scientists are continuing to study how cannabinoids may influence metabolism, inflammation, and energy balance. For now, the evidence points to CBD playing a supportive role, particularly through its effects on inflammation and oxidative stress. 

Further research is needed and Realm of Caring has several opportunities for you to join (and win gift cards)! Visit our research participation page to find out more.

Menopause is a natural transition that most women experience between the ages of 45 and 55. It occurs 12 months after cessation of a woman’s final menstrual cycle; following this time period, a woman enters postmenopause. The stage leading up to menopause, known as perimenopause, often begins in the early 40s (however may start in their 30s) and brings its own set of challenges. During this time, fluctuating hormones can disrupt sleep, mood, energy, and cognitive clarity, leaving many women feeling out of sync with their bodies and minds. 

 

In fact, studies suggest that nearly 85% of women experience symptoms during menopause, varying in severity and type to include: hot flashes, night sweats, sleep disturbances, mood swings, and decreased libido. As awareness grows, many women are seeking natural, evidence-informed strategies to support their well-being. Two emerging areas of interest are cannabinoids and functional mushrooms, which may complement traditional approaches and promote balance during this transitional period.

 

Understanding Hormonal Changes and the Endocannabinoid System

 

The hormonal fluctuations of perimenopause and menopause impact nearly every system in the body. Declining estrogen levels can lead to sleep disruptions, mood changes, brain fog, and decreased bone density. Interestingly, estrogen also interacts with the endocannabinoid system (ECS), a biological system that regulates balance across multiple physiological processes.

 

Research indicates that during menopause, cannabinoid receptor expression and endocannabinoids levels are altered. Therefore, the ECS may serve as a potential therapeutic target in preventing the effects of menopause-related diseases such as obesity, osteoporosis, cardiovascular disease, and cancer-types. This is where phytocannabinoids from plants such as cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabigerol (CBG), and cannabichromene (CBC) (among others) may help to regulate the ECS. 

 

How Cannabinoids May Help

 

Cannabinoids interact with ECS receptors throughout the body, influencing everything from mood and sleep to immune response and pain management. Here is a closer look at how they may support common symptoms of perimenopause and menopause:

 

Mood and Anxiety

CBD has been shown to modulate serotonin and GABA activity, neurotransmitters responsible for regulating mood and reducing anxiety. Many women report improvements in stress, irritability, and emotional instability during perimenopause after using CBD or balanced cannabinoid formulas.

 

Sleep and Night Sweats

THC can promote sleep and reduce nighttime disturbances, while CBD may help regulate sleep-wake cycles without sedation. While limited in research and mostly anecdotal to date, CBD has shown to have “significant and unexpected improvements” in excessive sweating. CBD’s interaction with serotonin receptors may play a role in temperature regulation, which may also benefit hot flashes. 

 

Muscle, Joint, and Bone Health

Several cannabinoids exhibit anti-inflammatory properties that may ease joint and muscle pain. Some studies suggest that cannabinoids can even support bone health by preventing bone degenerative conditions such as osteoporosis. CBD specifically may aid in the repair of bone fractures and increase bone mass.

 

Cognitive Support

As estrogen declines, some women experience “brain fog” or mild cognitive changes. Cannabinoids’ antioxidant and neuroprotective effects may help preserve mental clarity and support overall brain function.

 

Gastrointestinal Health and Metabolism

CBD may reduce gut inflammation, improve immune response, and support metabolic balance. This may help manage weight fluctuations through the browning of white adipose tissue and prohibiting oxidative stress to lower the risk of Type 2 Diabetes, often associated with menopause.

 

Sexual Health

Cannabinoids may help with vaginal discomfort, low libido, and painful intercourse by reducing spasms and enhancing relaxation. Products like topical creams and suppositories interact directly with female ECS receptors, bypassing metabolism and supporting local tissue health.

 

Functional Mushrooms for Hormonal and Emotional Balance

 

Functional mushrooms, long celebrated in traditional medicine, are gaining attention for their adaptogenic properties, which may help women navigate hormonal changes with more ease. Key mushrooms include:

 

• Reishi (Ganoderma lucidum): Known as the “mushroom of immortality,” reishi may support stress response, immune function, and sleep quality.
• Lion’s Mane (Hericium erinaceus): Celebrated for neurotrophic effects, it may enhance cognition, memory, and mood.
• Turkey Tail (Coriolus versicolor): Rich in antioxidants and immune-supportive compounds, it may help reduce inflammation and promote gut health.
• Cordyceps (Cordyceps sinensis): Traditionally used to improve energy, stamina, and respiratory function, cordyceps may also support sexual and metabolic health.
• Chaga (Inonotus obliquus): High in antioxidants, chaga may protect against oxidative stress and support cardiovascular health.

 

Combining mushrooms with other wellness practices may promote resilience, emotional stability, and cognitive support during perimenopause and menopause.

 

A Natural Synergy: Cannabinoids Meet Functional Mushrooms

 

Many women are now exploring the combined benefits of cannabinoids, functional mushrooms, and other herbal supplements for holistic support. According to a leading brand in women’s wellness, Opal & Joy, their functional mushroom and cannabinoid blends are specifically formulated to support the female endocannabinoid and endocrine systems, offering potential benefits for mood, sleep, and hormonal balance.

 

The brand was born out of co-founder Tiffany Tompkins’ acute and difficult personal experience with early perimenopause symptoms—including severe sleep disruptions, anxiety, hot flashes, joint pain, and more—starting in her late thirties. 

 

Having spent the last decade working in hemp and cannabis media, co-founder Melissa Zissou suggested Tiffany try CBD, which helped to alleviate the intensity of some of her symptoms. This led them to create a range of premium, clean and targeted sleep supplements that are clinically formulated using scientifically studied ingredients, including Ashwagandha, reishi, passionflower, full-spectrum CBD, the terpene linalool and more. 

 

“Sleep is everything,” explains Tiffany, “when you don’t get enough sleep, all your symptoms are compounded. Studies show that up to 60% of women suffer from sleep disturbances during perimenopause. Our products are designed to help you get the deep, restorative sleep you need to show up for yourself.”

 

The synergy of cannabinoids, mushrooms, and herbal supplements may help regulate stress responses, inflammation, and nervous system function to promote better sleep and create a foundation for greater overall well-being during the menopausal transition. “Everything we do is about supporting your body’s natural rhythms through clean, plant-based solutions — no gimmicks, no hormone spikes, no synthetic junk,” says Tiffany.

 

“Our mission is to encourage women to be ‘Perimenoproud™’, which aligns with the idea that the transition is not a breakdown, but a time of empowerment and mid-life magic,” says Melissa. “Being Perimenoproud means embracing change, supporting each other, and demanding products, conversations and science that actually serves women.”

 

Tips for Getting Started

 

1. Start low and go slow: Everyone responds differently; begin with small doses of cannabinoids or mushroom supplements.
2. Track your symptoms: Note improvements in mood, sleep, and energy to find the right combination.
3. Consult a professional: Speak with a qualified healthcare provider or our Care Team to individualize your therapy.
4. Choose high-quality products: Look for third-party tested supplements and cannabinoid products from trusted sources.

 

Concluding Thoughts

 

Perimenopause and menopause are life stages that can bring significant challenges, but also opportunities for self-care and holistic wellness. Evidence suggests that cannabinoids and functional mushrooms may support hormone balance, mood, sleep, cognition, and overall vitality. By exploring these natural tools thoughtfully, women can find individualized strategies to thrive during this transition and embrace it as a new chapter of empowered living.

Many clients come to Realm of Caring looking for help in improving their quality of sleep. The great news is that research is continuing to show us that cannabinoid therapy may help. Certain cannabinoids have shown through studies the ability to benefit our sleep-wake cycles, decrease nightmares, lessen the conditions that interfere with our sleep, and assist in actually falling asleep. 

 

Before we go on, let’s get into some background information and understanding. 

 

Sleep Challenges in America

 

Circadian rhythm is our biological rhythm in a 24-hour period, coming from the Latin circa meaning around and dies meaning day. The most commonly known is the sleep-wake cycle, which in chronobiology, is tied to day and night or lightness and darkness. An out-of-sync circadian cycle may be associated with poor health outcomes. 

 

Insomnia is recognized by the American Psychiatric Association as the most common sleep disorder, involving problems getting to sleep or staying asleep with symptoms being episodic, persistent, and/or recurrent. This sleep disorder is known to cause distress or impairment. A survey published by the American Academy of Sleep Medicine found that 12% Americans reported a diagnosis of chronic insomnia. 

 

The National Sleep Foundation shared the following statistics in their 2025 report:

 

• 6 in 10 adults do not get enough sleep
• Nearly 4 in 10 adults struggle to fall asleep at least 3 nights per week
• Almost half of adults experience difficulty staying asleep at least 3 nights per week 
• 3 in 4 adults say good quality sleep positively impacts their ability to flourish – with women more often reporting stronger perceived benefits

 

What does our Endocannabinoid System have to do with Sleep? 

 

Our Endocannabinoid System (ECS) is composed of endocannabinoids, as well as two distinct receptors known as CB1 and CB2, and enzymes responsible for the metabolism of endocannabinoids. It has been found that the expression pattern of CB1 and CB2 receptors are influenced by light-dark cycles and therefore appear to align with circadian rhythms. Furthermore, it has been shown in studies with rodents that the ECS may potentially modulate those rhythms to promote sleep. 

 

Phytocannabinoids may provide an indirect benefit to sleep through mitigating conditions that often disrupt sleep. Major cannabinoids found in the cannabis plant, such as cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may reduce anxiety, inflammation, and/or pain – all factors that may disrupt sleep. 

 

CBD and Sleep

 

Although CBD is not a naturally sedative molecule on its own, research has shown that high quantities may have “sedative-like qualities”, potentially due to the effect on cortisol levels. 

 

CBD also has therapeutic properties that have the potential to mitigate symptoms that interfere with sleep. It also has the potential to improve sleep-wake cycles leading to an increase in the percentage of total sleep over time.

 

Among the several researched properties, CBD may benefit as an anxiolytic, anti-inflammatory, and analgesic. The anxiolytic properties of CBD may help to improve sleep by mitigating anxiety or stress-induced insomnia. Stress induces a sleep-related feature known as rapid eye movement (or REM) sleep rebound, this is an increase in REM sleep during the nightly sleep cycles. People experiencing REM sleep rebound may spend more time in REM then they would during a night of normal, healthy sleep.

 

Inflammation is a root cause of autoimmune disorders including arthritis, diabetes, irritable bowel syndrome (IBS), crohn’s disease, and others – all which have an effect on body clock function that can lead to sleep disorders. A study by Northwestern found in mice this link between inflammation and what controls the body clock. By limiting this inflammation, we may lessen the effects on our body clock functions and have more restful sleep. 

 

A study in 2005 showed that people reporting insomnia symptoms are at least three times more likely to have a chronic painful physical condition. These events may then become cyclical in that pain may disrupt sleep and sleep deprivation can increase pain perception. In the majority of animal studies, CBD has been known to exert analgesic effects; co-administering with THC may provide more benefit to this therapeutic action. 

 

Our circadian rhythm aligns our sleep and wakefulness with day and night to provide stability in restorative rest that enables increased daytime activity. Low doses of CBD may be associated with wakefulness to help our focus and cognition during the day. Studies show that therapeutic levels of CBD administration may increase total sleep time and decrease frequency of arousals at night – leading to an increase in total percentage of sleep over time. 

 

THC and Sleep

 

In comparison to CBD, THC has shown in studies as having an affect on mental and physical sedation, even in low amounts. THC also has positive therapeutic benefits that may lead to better sleep.

 

Nightmares are associated with posttraumatic stress disorder (PTSD) often resulting in this being considered a “treatment-resistant” condition. Initial research has shown the benefit cannabinoids can have in managing nightmares linked with PTSD. A study with military veterans and prison inmates receiving Nabilone, a synthetic form of THC, found a reduction in nightmare presence and intensity. This increased participants’ hours of sleep per night. 

 

Just as mentioned with CBD, THC is also beneficial for mitigating pain-induced insomnia or wakefulness. When it comes to pain studies and medical cannabis with significant THC content, benefits consistently show moderate to high symptom management of chronic pain. 

 

A normal amount of apneic events in a healthy individual is about 4 per hour while asleep. Sleep apnea is the most prevalent form of sleep-disordered breathing in the United States and a number of animal and human studies have been conducted to examine cannabinoids as potential therapeutic alternatives to continued positive airway pressure (CPAP) machines, which are currently being utilized.

 

THC shares properties of the endocannabinoid Oleamide, which benefits apneic events. Results in one animal study showed that both the endocannabinoid Oleamide and the exogenous cannabinoid THC reduced apneic events, suggesting therapeutic promise for those who suffer with sleep apnea. 

 

Limitations in Cannabinoid Research

 

A recent systematic review on cannabis and sleep architecture highlighted the mixed results that are available in literature. While surveys suggest that sleep is the most commonly reported targeted symptom to address with cannabis use and 85% of medicinal users reporting sleep improvement, studying the effect of cannabis on sleep is complicated. Chronic users may need higher quantities of THC and find it necessary for sleep, while first-time users may have an unsavory experience due to limited available guidance. 

 

Next Steps and Getting Started

 

Here are some best practices if you are looking to incorporate cannabinoid therapy as a tool:

 

• Start low and go slow – find your therapeutic dose at the lowest amount.
• Quality of product matters, use this guide to vet product companies before you buy.
• Pairing cannabinoids with adaptogens (like functional mushrooms) may provide additional benefit, but this remains an emerging frontier. If you want to bring this up to your doctor but don’t know where to start, we can help. 
• Document your journey through journaling.
• Join an available research study to further our understanding of cannabinoids and sleep.

 

Realm of Caring’s no cost hotline is available to you! Reach out for support today. 

 

Sexual Health Awareness Month and Libido

 

Sexual Health Awareness Month is a time to highlight how intimacy and desire contribute to overall wellbeing. Libido, the natural drive for sex, can shift at different life stages and is influenced by everything from stress to hormones. For many people, especially women navigating perimenopause and menopause, these changes can feel disruptive. Cannabis has become a promising aid for sexual health, with growing research and personal accounts suggesting it may help rekindle desire and improve satisfaction.

 

 

How Cannabis May Enhance Libido

 

Research suggests cannabis affects libido through multiple pathways, both physical and psychological.

 

Reducing Stress and Anxiety

Anxiety is one of the most common barriers to sexual arousal. Cannabis has been shown to promote relaxation and reduce inhibitions, helping people feel more present during intimacy. A 2023 study published in Journal of Cannabis Research found that cannabis users often experienced greater sexual desire, stronger orgasms, and higher overall satisfaction compared to non-users.

 

Heightening Sensory Experience

Cannabis can enhance sensory perception, making touch and physical intimacy feel more intense. This may explain why many users report increased arousal and more pleasurable sexual encounters.

 

Supporting Women in Perimenopause and Menopause

Declining estrogen levels during menopause can cause vaginal dryness, pain during sex, and reduced libido. Cannabis’s anti-inflammatory and analgesic properties may help alleviate discomfort. In one study of women with sexual dysfunction, those who used cannabis before sex reported better lubrication and greater satisfaction. Surveys of menopausal women also show many use cannabis to manage symptoms like mood changes, sleep disruption, and low libido.

 

Effects for Men

Men also report benefits from cannabis use, including increased sexual frequency and satisfaction. However, moderation is key. Research suggests that while low to moderate use may enhance libido and performance, heavy or chronic use could have drawbacks, such as impacts on testosterone or erectile function.

 

 

The Role of the Endocannabinoid System

 

The endocannabinoid system regulates mood, stress, and reproduction, and may interact with reproductive hormones like estrogen. Researchers are still exploring how cannabis affects these pathways, but early findings suggest cannabis may help restore balance during times of hormonal fluctuation, such as perimenopause.

 

 

What the Research Tells Us

 

Self-reported data: Much of the evidence comes from surveys, where participants consistently report improved sexual experiences with cannabis use.

 

Clinical trials: Controlled studies are still limited, but the data so far supports the idea that cannabis can positively influence arousal, lubrication, orgasm, and overall sexual satisfaction.

 

Caution with dosage: Cannabis often follows a biphasic effect—low doses may enhance libido, while high doses could dampen it.

 

 

Practical Tips for Using Cannabis for Sexual Health

 

• Start low and go slow, especially with THC.
• Reach out for support to understand the different forms and what might be best for you (inhaled, edible, topical).
• Use cannabis intentionally before sexual activity to maximize benefits.
• Pair cannabis use with lifestyle strategies like open communication, stress management, and healthy sleep.
• Consult with a healthcare provider before beginning or adjusting cannabis use, especially if taking other medications.

 

 

Why This Matters During Sexual Health Awareness Month

 

Sexual health is an important but often overlooked dimension of wellness. For people navigating changes in libido—whether due to stress, age, or hormonal transitions—cannabis offers a promising option for support. While more research is needed, the evidence so far highlights cannabis as a potential tool to enhance intimacy, reduce barriers like pain and anxiety, and support healthier, more fulfilling sexual experiences.

 

Cannabis is not a cure-all, but it can be an empowering aid in sexual health for both men and women. During Sexual Health Awareness Month, conversations like these are vital for breaking stigma and offering hope. If you’re curious about how cannabis might support your sexual wellbeing, consider exploring the research further and connecting with resources like the Cannabis Health Research Initiative.

As researchers and educators at Realm of Caring, we believe in a holistic, evidence-informed approach to supporting healthy aging and addressing Alzheimer’s disease. While aging is inevitable, there are natural strategies that show promising potential both for maintaining cognitive health and for helping manage symptoms in Alzheimer’s. In this post, we’ll explore what current research says about cannabinoids and complementary botanicals (including functional mushrooms) for brain health, quality of life, and aging well.

 

Understanding the Challenge: Aging, Alzheimer’s, and Brain Health

 

As we age, our bodies undergo changes. Skin becomes less elastic, muscle mass decreases, sleep patterns shift, and chronic conditions like cardiovascular disease and Alzheimer’s become more likely. Alzheimer’s disease is a progressive neurodegenerative disorder impacting memory, thinking, and behavior. There is no cure yet, but interventions that slow progression, reduce symptoms, or support quality of life are critically important. Statistics estimate millions of Americans are affected, and that number is expected to grow.

 

CBD & Cannabinoids: What the Research Suggests

 

Neuroprotection and Antioxidant Effects

 

One of the mechanisms by which cannabidiol (CBD) may help is by mitigating oxidative stress and excitotoxicity – both key contributors in Alzheimer’s pathology. Research shows that CBD can block or modulate harmful glutamate levels, acting comparably in some experiments to industrial antioxidants. This helps reduce damage to neurons. 

 

Interactions with Immune Cells & Inflammatory Pathways

 

The CB2 receptors, part of the endocannabinoid system, are expressed in microglial cells (the brain’s immune cells). Activation of these receptors by cannabinoids may help reduce neuroinflammation, which is a driving force in Alzheimer’s disease. By modulating inflammatory responses, CBD may help slow the progression of neurodegenerative events. 

 

Managing Behavioral & Lifestyle Symptoms

 

Neuropsychiatric symptoms such as sleep disturbances, agitation, depression, and anxiety often accompany Alzheimer’s. CBD and THC:CBD combinations have been studied for their effects on improved sleep quality through reducing sleep latency, lengthening sleep duration, and limiting awakenings. Some observational studies show reduced agitation and better mood in Alzheimer’s patients using cannabinoid extracts under supervision. 

 

Healthy Aging Beyond Alzheimer’s

 

For people aging without Alzheimer’s (or before onset), cannabinoids have been studied for benefits with skin health (hydration, antioxidant effect, anti-inflammatory), appetite regulation, cardiovascular health (anti‐inflammatory, antioxidant), metabolic health, pain and arthritis, muscle maintenance, and sleep quality. These benefits may help delay or mitigate risk factors associated with Alzheimer’s.

 

Practical Considerations & Safety for Cannabinoid Therapy

 

• Start low, go slow: Individual response to cannabinoids can vary. It is important to seek individualized support.

• Source and quality matter: Products should be high‐quality, tested for purity, consistent cannabinoid content, and free of contaminants. Check out the Quality of Product Matters Guide.

• Interactions: CBD may interact with medications; immune status, liver health, overall health status must be considered. Consult with you physician or a pharmacist if you are taking several medications.

• Legality and regulation: Laws vary by state and country; ensure compliance and proper documentation. Realm of Caring’s Observational Research Registry (ORR) is helping to gather real‐world data on safety and outcomes.

 

Complementary Botanicals & Functional Mushrooms

 

While cannabinoids show promise, combining them with other plant botanicals and functional mushrooms may offer synergistic effects for brain health and aging:

 

• Botanicals like turmeric, ginkgo biloba, bacopa have antioxidant, anti‐inflammatory, and neuroprotective properties in preliminary studies. When used appropriately, they may support cognition, memory, and vascular health.

• Functional mushrooms such as lion’s mane, reishi, cordyceps, and chaga are gaining attention. Lion’s mane, for example, has compounds that may stimulate nerve growth factor (NGF), which supports neuron health; anti‐inflammatory and antioxidant effects have been observed in animal and small human trials. Reishi and chaga add immune modulation and reduce oxidative stress, which are valuable in the context of Alzheimer’s and aging.

 

Toward a Holistic Plan

 

Pulling all this together, here’s what a holistic plan might look like:

 

• Adopt a nutrient‐rich, anti‐inflammatory diet (fruits, vegetables, healthy fats, mushrooms, botanicals).

• Include cannabinoids (CBD, or balanced THC:CBD in legal regions) under guidance, targeting symptoms like sleep disturbances, mood, inflammation.

• Incorporate botanicals and functional mushrooms as adjuncts for neuroprotection and immune support.

• Prioritize lifestyle factors: physical activity, restful sleep, stress management, social connection.

• Monitor, adjust, and always consult qualified professionals to tailor choices, monitor efficacy, and avoid adverse effects.

 

At Realm of Caring, our mission is to support you with rigorous research, client education, and community care. As new evidence emerges, we hope to offer increasing clarity on how CBD, other cannabinoids, botanicals, and functional mushrooms may be integrated into a safe, holistic regimen for Alzheimer’s and healthy aging. If you have questions about specific products, dosing, or strategies, our care specialists are available to help.

 

Inflammation is at the root of many health challenges, from arthritis and gut issues to brain fog and chronic pain. While inflammation is a natural defense mechanism, when it becomes chronic, it can fuel disease progression and significantly impact quality of life. Increasingly, research is showing that cannabis compounds may help regulate inflammation and support the body in finding balance.

 

The Endocannabinoid System and Inflammation

 

The endocannabinoid system (ECS) is a network of receptors, endocannabinoids, and enzymes that work to maintain homeostasis in the body. Among several other physiological actions, the ECS is a modulator of immune system activity. 

 

Cannabinoids from the cannabis plant interact with the ECS, potentially dialing down excessive inflammation. Research has found that cannabinoids can modulate immune cell activity, reduce oxidative stress, and calm overactive inflammatory pathways.

 

How CBD Might Help with Inflammation

 

CBD (cannabidiol) doesn’t produce intoxication, but it does have powerful anti-inflammatory effects. Studies show that CBD may:

 

• Reduce neurogenic inflammation, which is linked to chronic inflammatory diseases such as multiple sclerosis (MS), migraine, diabetes, and Parkinson’s disease.
• Calm intestinal inflammation by interacting with serotonin receptors and the gut’s immune system. This may assist in providing relief in conditions such as Crohn’s disease, inflammatory bowel disease (IBD), and ulcerative colitis.
• Benefits the healing process of joints and muscles by interacting with inflammatory mediator receptors and pathways. CBD may help control localized inflammation that causes pain and tissue damage in arthritic joints as well as alleviate muscle soreness after exercise or injury.

 

Consistent administration seems to be key, Researchers note that regular CBD use may build up its effects over time, rather than acting as a quick fix. Explore more on CBD and inflammation in our research library.

 

THC, Microdosing, and Pain Relief

 

THC is often associated with its euphoric effects, but in smaller amounts (microdosing) it may relieve pain and inflammation without noticeable intoxication. THC activates CB2 receptors in the immune system, which can reduce swelling and inflammatory signaling.

 

For some people, combining CBD with very low doses of THC (as in full-spectrum CBD products) may provide a more comprehensive anti-inflammatory effect. Research suggests that this synergy could support pain relief in arthritis, inflammatory bowel diseases, and neuro-inflammatory conditions.

 

CBDA for Inflammation

 

Cannabidiolic acid (CBDA) is one of three cannabinoid precursor compounds converted from Cannabigerolic acid (CBGA). CBGA also converts to the precursor compounds Tetrahydrocannabinolic acid (THCA) and Cannabichromenic acid (CBCA) or may convert to its non-acidic form, Cannabigerol (CBG).

 

CBDA inhibits the COX-2 Enzyme. These enzymes are associated with inflammation after injury or infection. Therefore, by blocking COX-2 Enzymes, CBDA may relieve inflammation and associated pain. In a rodent study, equivalent amounts of CBD and CBDA were administered to test efficiency in reducing hyperalgesia. The low amount of CBD was not efficient in reducing this increased sensitivity to pain when exposed to normal stimuli. The CBDA, on the other hand, did reduce hyperalgesia at that same low amount. In the same study, amounts of THC and CBDA so low that they were deemed “ineffective” were administered. When these ineffective, low amounts were combined it was shown in the animal models to have anti-inflammatory and anti-hyperalgesia effects on acute inflammation.

 

CBG for Inflammation

 

Cannabigerol (CBG) was first discovered and synthesized by Raphael Mechoulam and Yehiel Gaoni in 1964. As previously mentioned, it is derived from cannabigerolic acid (CBGA) once heated, becoming a very stable molecule.

 

Animal studies have shown CBG to reduce the effects of inflammatory bowel disease. Several studies, in vitro and in animal models, have also shown CBG to have neuroprotective potential for reducing the severity of neurological illnesses, such as Huntington disease (HD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and MS. The anti-inflammatory and antioxidant benefits contribute to reducing glutamate-induced oxidative stress and cell death, as shown in mouse models.

 

Consistency Matters

 

One of the most important takeaways from the research is that consistent administration may be necessary to witness anti-inflammatory benefit. Like many wellness strategies, cannabinoids may take time to build their effects. Sticking to a routine and keeping track of responses can help individuals find what works best for them.

 

Concluding Thoughts

 

While promising evidence is mounting for the use of several cannabinoids for inflammation-related conditions, more large-scale clinical trials are needed. Cannabinoids such as CBD, THC, CBDA, and CBG show real potential in calming inflammation, relieving pain, and improving quality of life for people living with acute and chronic inflammatory conditions. The key is understanding how these compounds interact with your unique body and doing so safely with guidance.